These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 1962651)

  • 1. Impact of epoetin beta on dialyzer clearance and heparin requirements.
    Spinowitz BS; Arslanian J; Charytan C; Golden RA; Rascoff J; Galler M
    Am J Kidney Dis; 1991 Dec; 18(6):668-73. PubMed ID: 1962651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease.
    Ifudu O; Feldman J; Friedman EA
    N Engl J Med; 1996 Feb; 334(7):420-5. PubMed ID: 8552143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of erythropoietin on the dialysis prescription.
    Van Wyck DB
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):71-5. PubMed ID: 1928083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of erythropoietin therapy on diet and dialysis clearances in hemodialysis patients.
    Kaupke CJ; Vaziri ND; Sampson JR; Atkins K
    Int J Artif Organs; 1990 Apr; 13(4):218-22. PubMed ID: 2373550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dialyzer urea and creatinine clearances are not significantly altered in erythropoietin treated maintenance hemodialysis patients.
    Delano BG; Lundin AP; Galonsky R; Quinn-Cefaro RM; Rao TK; Friedman EA
    ASAIO Trans; 1990; 36(1):36-9. PubMed ID: 2306389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hematocrit influence on peritoneal dialysis effectiveness during recombinant human erythropoietin treatment in patients with chronic renal failure.
    Ksiazek A; Baranowska-Daca E
    Perit Dial Int; 1993; 13 Suppl 2():S550-2. PubMed ID: 8399662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. Report of National Cooperative rHu Erythropoietin Study Group.
    Nissenson AR
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):24-33. PubMed ID: 1928075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anemia management of adult hemodialysis patients in the US results: from the 1997 ESRD Core Indicators Project.
    Frankenfield D; Johnson CA; Wish JB; Rocco MV; Madore F; Owen WF
    Kidney Int; 2000 Feb; 57(2):578-89. PubMed ID: 10652035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severity of AIDS and the response to EPO in uremia.
    Ifudu O; Matthew JJ; Mayers JD; Macey LJ; Brezsnyak W; Reydel C; McClendon E; Surgrue T; Rao S; Friedman EA
    Am J Kidney Dis; 1997 Jul; 30(1):28-35. PubMed ID: 9214398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous erythropoietin results in lower dose and equivalent hematocrit levels among adult hemodialysis patients: Results from the 1998 End-Stage Renal Disease Core Indicators Project.
    McClellan WM; Frankenfield DL; Wish JB; Rocco MV; Johnson CA; Owen WF;
    Am J Kidney Dis; 2001 May; 37(5):E36. PubMed ID: 11325701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of epoetin alfa therapy for anemia of end-stage renal disease.
    Moran LJ; Carey P; Johnson CA
    Am J Hosp Pharm; 1992 Jun; 49(6):1451-4. PubMed ID: 1529988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efficacy of recombinant human erythropoietin in hemodialysis patients.
    Mohini R
    Semin Nephrol; 1989 Mar; 9(1 Suppl 1):16-21. PubMed ID: 2648516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemoglobin response and influence on left ventricular hypertrophy after 24-week treatment of a biosimilar epoetin-alfa in hemodialysis patients with anemia.
    Thanakitcharu P; Siriwiwatanakul N
    J Med Assoc Thai; 2007 Dec; 90(12):2574-86. PubMed ID: 18386706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Normalization of hematocrit in hemodialysis patients with cardiac disease does not increase blood pressure.
    Conlon PJ; Kovalik E; Schumm D; Minda S; Schwab SJ
    Ren Fail; 2000; 22(4):435-44. PubMed ID: 10901181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter clinical trial of epoetin beta for anemia of end-stage renal disease.
    Bennett WM
    J Am Soc Nephrol; 1991 Jan; 1(7):990-8. PubMed ID: 1883969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epoetin omega for treatment of anemia in maintenance hemodialysis patients.
    Sikole A; Spasovski G; Zafirov D; Polenakovic M
    Clin Nephrol; 2002 Mar; 57(3):237-45. PubMed ID: 11924756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current management of anemia in adult hemodialysis patients with end-stage renal disease.
    Frankenfield DL; Johnson CA
    Am J Health Syst Pharm; 2002 Mar; 59(5):429-35. PubMed ID: 11887409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case management of the anemic patient: epoetin alfa--focus on adequacy of dialysis.
    Erlich L
    ANNA J; 1993 Apr; 20(2):181-4. PubMed ID: 8512376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin.
    Besarab A; Bolton WK; Browne JK; Egrie JC; Nissenson AR; Okamoto DM; Schwab SJ; Goodkin DA
    N Engl J Med; 1998 Aug; 339(9):584-90. PubMed ID: 9718377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epoetin requirements predict mortality in hemodialysis patients.
    Zhang Y; Thamer M; Stefanik K; Kaufman J; Cotter DJ
    Am J Kidney Dis; 2004 Nov; 44(5):866-76. PubMed ID: 15492953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.